SEARCH:   Advanced

Blood, 15 December 2006, Vol. 108, No. 13, pp. 4194-4197. Prepublished online as a Blood First Edition Paper on August 31, 2006; DOI 10.1182/blood-2006-06-029355. This Article Full Text (PDF) Supplemental Table and Figures Erratum (v109,p2717) All Versions of this Article: blood-2006-06-029355v1 108/13/4194    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moreaux, J. Articles by Klein, B. Search for Related Content PubMed PubMed Citation Articles by Moreaux, J. Articles by Klein, B. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 20, 2006 Accepted August 2, 2006 CD200 is a new prognostic factor in Multiple Myeloma Jerome Moreaux, Dirk Hose, Thierry Reme, Eric Jourdan, Michael Hundemer, Eric Legouffe, Philippe Moine, Philippe Bourin, Marion Moos, Jill Corre, Thomas Mohler, John De Vos, Jean francois Rossi, Hartmut Goldschmidt, and Bernard Klein* CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France Medizinische Klinik und Poliklinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany CHU Nimes, Internal Medicine Department B, Nimes, France CHU Montpellier, Department of Hematology and Clinical Oncology, Montpellier, France Laboratoire de Therapie Cellulaire-Etablissement Francais du sang, Toulouse * Corresponding author; email: klein{at}montp.inserm.fr. Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMC) of 112 patients with newly-diagnosed multiple myeloma (MM). The CD200 gene was either absent or present (Affymetrix call) in 22% and 78% of MMC, respectively. The CD200 gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Patients with CD200absent MMC have an increased event free survival (24 months) compared to patients with CD200present MMC (14 months), after high-dose therapy and stem cell transplantation. In a Cox-proportional-hazard model, the absence or presence of CD200 expression in MMC is predictive for EFS for patients independently of ISS stage or B2M serum levels. Thus, CD200 is an independent prognosis factor for patients with MM that could represent a new therapeutic target in MM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: No tumor-CD200 expression, please! Reginald Gorczynski Blood 2006 108: 3958. [Full Text] [PDF] This article has been cited by other articles: S. G. Holtan, D. J. Creedon, P. Haluska, and S. N. Markovic Cancer and Pregnancy: Parallels in Growth, Invasion, and Immune Modulation and Implications for Cancer Therapeutic Agents Mayo Clin. Proc., November 1, 2009; 84(11): 985 - 1000. [Abstract] [Full Text] [PDF] R. Mihrshahi, A. N. Barclay, and M. H. Brown Essential Roles for Dok2 and RasGAP in CD200 Receptor-Mediated Regulation of Human Myeloid Cells J. Immunol., October 15, 2009; 183(8): 4879 - 4886. [Abstract] [Full Text] [PDF] R. M. Gorczynski, Z. Chen, W. He, I. Khatri, Y. Sun, K. Yu, and I. Boudakov Expression of a CD200 Transgene Is Necessary for Induction but Not Maintenance of Tolerance to Cardiac and Skin Allografts J. Immunol., August 1, 2009; 183(3): 1560 - 1568. [Abstract] [Full Text] [PDF] A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica, March 1, 2008; 93(3): 431 - 438. [Abstract] [Full Text] [PDF] B. Delorme, J. Ringe, N. Gallay, Y. Le Vern, D. Kerboeuf, C. Jorgensen, P. Rosset, L. Sensebe, P. Layrolle, T. Haupl, et al. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells Blood, March 1, 2008; 111(5): 2631 - 2635. [Abstract] [Full Text] [PDF] A. Kretz-Rommel, F. Qin, N. Dakappagari, R. Cofiell, S. J. Faas, and K. S. Bowdish Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy J. Immunol., January 15, 2008; 180(2): 699 - 705. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020